Cyltezo (adalimumab-adbm) is a biosimilar to Humira (adalimumab), an anti-TNF-α monoclonal antibody used for the treatment of multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

A biosimilar is a product that is highly similar to an FDA-approved biologic, known as the reference product. Biosimilars have no clinically meaningful differences in safety, purity or potency compared to the reference product.

Cyltezo (adalimumab-adbm) was the second Humira (adalimumab) biosimilar approved by the FDA.

FDA approved biosimilars to Humira include:

• Amjevita (adalimumab-atto)
• Cyltezo (adalimumab-adbm)
• Hyrimoz (adalimumab-adaz)
• Hadlima (adalimumab-bwwd)
• Abrilada (adalimumab-afzb)
• Hulio (adalimumab-fkjp)
• Yusimry (adalimumab-aqvh)
• Yuflyma (adalimumab-aaty)

The approved indications for Humira and Cyltezo are not the same.

Like Humira, Cyltezo is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Unlike Humira, Cyltezo is not approved for the treatment of uveitis.

Indications may also differ across population groups.

The following table compares the approved indications for Humira and Cyltezo:

Cyltezo is an interchangeable product with Humira. A biosimilar with an Interchangeable designation can be auto-substituted by a pharmacist for the reference product.

Cyltezo and Humira are both administered via subcutaneous injection.

• Cyltezo is available as a single-dose prefilled syringe and a single dose prefilled pen
• Humira is available as a single-dose prefilled pen, prefilled syringe, and single-dose vial.

See What Are Biosimilars? Top Facts You May Not Know